Similar articles

• [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].

  Pletscher A, Bartholini G, Gey KF, Jenni A. Pletscher A, et al. Schweiz Med Wochenschr. 1970 May 9;100(19):797-804. Schweiz Med Wochenschr. 1970. PMID: 4924275 Review. German. No abstract available.
• [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].

  Gattringer B, Steinhäusl H. Gattringer B, et al. Wien Med Wochenschr. 1972 Jun 17;122(25):369-71. Wien Med Wochenschr. 1972. PMID: 4558132 German. No abstract available.
• Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.

  Knutsson E, Mårtensson A. Knutsson E, et al. Scand J Rehabil Med. 1974;6(2):89-93. Scand J Rehabil Med. 1974. PMID: 4837060 No abstract available.
• L-Dopa, B 6 , and alpha-methyldopa hydrazine.

  Klawans HL Jr, Ringel SP. Klawans HL Jr, et al. Confin Neurol. 1973;35(3):186-92. Confin Neurol. 1973. PMID: 4712885 No abstract available.
• [Factors which influence infavourably l-dopa treatment].

  Presthus J. Presthus J. Tidsskr Nor Laegeforen. 1973 Oct 10;93(28):2115-6. Tidsskr Nor Laegeforen. 1973. PMID: 4590071 Review. Norwegian. No abstract available.